[go: up one dir, main page]

AR026421A1 - Compuesto de imidazol como inhibidores de la fosfodiesterasa vii - Google Patents

Compuesto de imidazol como inhibidores de la fosfodiesterasa vii

Info

Publication number
AR026421A1
AR026421A1 ARP000105929A ARP000105929A AR026421A1 AR 026421 A1 AR026421 A1 AR 026421A1 AR P000105929 A ARP000105929 A AR P000105929A AR P000105929 A ARP000105929 A AR P000105929A AR 026421 A1 AR026421 A1 AR 026421A1
Authority
AR
Argentina
Prior art keywords
inhibitors
phosphodiesterase vii
imidazol compound
imidazol
compound
Prior art date
Application number
ARP000105929A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR026421A1 publication Critical patent/AR026421A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)

Abstract

Compuestos de imidazol de formula 1 donde R1, R2 significan cada uno independientemente A1, OA1, SA1, o Hal A1 es H, A, alquenilo, cicloalquilo oalquilencicloalquilo, Hal F, Cl, Br, o I, y X es O, S, SO o SO2 y sus sales y/o solvatos fisiologicamente inofensivos como inhibidor de fosfodiesterasa VII ysu utilizacion para la obtencion de medicamentos.
ARP000105929A 1999-11-13 2000-11-10 Compuesto de imidazol como inhibidores de la fosfodiesterasa vii AR026421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19954707A DE19954707A1 (de) 1999-11-13 1999-11-13 Imidazolverbindungen als Phosphodiesterase VII-Hemmer

Publications (1)

Publication Number Publication Date
AR026421A1 true AR026421A1 (es) 2003-02-12

Family

ID=7928973

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105929A AR026421A1 (es) 1999-11-13 2000-11-10 Compuesto de imidazol como inhibidores de la fosfodiesterasa vii

Country Status (23)

Country Link
US (1) US6884800B1 (es)
EP (1) EP1228073B1 (es)
JP (1) JP4819272B2 (es)
KR (1) KR20020049051A (es)
CN (1) CN1390222A (es)
AR (1) AR026421A1 (es)
AT (1) ATE245653T1 (es)
AU (1) AU775886B2 (es)
BR (1) BR0015487A (es)
CA (1) CA2391087A1 (es)
CZ (1) CZ20021474A3 (es)
DE (2) DE19954707A1 (es)
DK (1) DK1228073T3 (es)
ES (1) ES2200968T3 (es)
HU (1) HUP0203422A3 (es)
MX (1) MXPA02004728A (es)
NO (1) NO20022232L (es)
PL (1) PL355098A1 (es)
PT (1) PT1228073E (es)
RU (1) RU2002113759A (es)
SK (1) SK6012002A3 (es)
WO (1) WO2001036425A2 (es)
ZA (1) ZA200204729B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
NZ580413A (en) * 2007-03-27 2012-11-30 Omeros Corp The use of pde7 inhibitors for the treatment of movement disorders
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ610925A (en) 2010-11-08 2015-10-30 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3652180B1 (en) 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
IL318817A (en) 2022-08-18 2025-04-01 Mitodicure Gmbh Use of a therapeutic agent with PHOSPHODIESTERASE-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exercise intolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2919271A (en) 1957-12-05 1959-12-29 Smith Kline French Lab 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5318965A (en) * 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity

Also Published As

Publication number Publication date
CN1390222A (zh) 2003-01-08
US6884800B1 (en) 2005-04-26
MXPA02004728A (es) 2002-08-30
KR20020049051A (ko) 2002-06-24
HUP0203422A2 (hu) 2003-02-28
HUP0203422A3 (en) 2004-12-28
CA2391087A1 (en) 2001-05-25
DE19954707A1 (de) 2001-05-17
EP1228073B1 (de) 2003-07-23
JP4819272B2 (ja) 2011-11-24
RU2002113759A (ru) 2004-01-10
AU1390701A (en) 2001-05-30
WO2001036425A3 (de) 2002-01-10
BR0015487A (pt) 2002-07-02
WO2001036425A2 (de) 2001-05-25
NO20022232D0 (no) 2002-05-10
DK1228073T3 (da) 2003-11-03
JP2003514821A (ja) 2003-04-22
ATE245653T1 (de) 2003-08-15
AU775886B2 (en) 2004-08-19
PL355098A1 (en) 2004-04-05
EP1228073A2 (de) 2002-08-07
DE50003036D1 (de) 2003-08-28
ZA200204729B (en) 2003-11-26
CZ20021474A3 (cs) 2002-07-17
NO20022232L (no) 2002-05-10
PT1228073E (pt) 2003-12-31
SK6012002A3 (en) 2002-09-10
ES2200968T3 (es) 2004-03-16

Similar Documents

Publication Publication Date Title
AR026421A1 (es) Compuesto de imidazol como inhibidores de la fosfodiesterasa vii
AR026351A1 (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii
DK0846686T3 (da) 1-phenylpyrazolderivater og deres anvendelse som parasiticide midler
TR200201506T2 (tr) Terapötik maddeler olarak kinaz inhibitörleri
NO20003969D0 (no) Antibakterielle midler
ATE248836T1 (de) Heterozyklische verbindungen als inhibitoren der rotamaseaktivität
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
NO20073956L (no) Pyrazolderivater for inhibering av CDK og GSK
CO5160347A1 (es) Derivados de acido carbamico
DK1300401T3 (da) Thiazolderivater til anvendelse som antiinflammatoriske midler
UY24010A1 (es) Nuevos pirrolocarbazoles
ES2192183T3 (es) Derivados de imidazopiridina como inhibidores de fosfodiesterasa vii.
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE69922009D1 (de) Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren
PT954521E (pt) Derivados do 4-¬(tien-3-il)metil|imidazole possuindo actividade agonista para o receptor alfa2-adrenergico
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
CO5680420A2 (es) Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
DE60234117D1 (de) 2-amino-4-pyridylmethyl-thiazolinderivate und ihre verwendung als induzierbare no-synthase inhibitoren
NO20023298D0 (no) Nye imidazolderivater
ECSP024375A (es) Derivados del 2-aminotiazolina y sus uso como inhibidores de no sintetasa
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
PT1115404E (pt) Utilizacao de antagonistas prostanoides para o tratamento de cefaleias primarias
FR2801055B1 (fr) Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
TR199903249T2 (xx) �l-5 inhibit�rleri olarak 6-Azaurasil t�revleri.

Legal Events

Date Code Title Description
FB Suspension of granting procedure